20-F: Inspira Technologies Reports 2025 Losses, Eyes Growth Amid Going Concern Doubts

Inspira Technologies, a medical device company, reported a net loss of $13.2 million for 2025, its first revenue of $289,000 from ART100 sales, and faces going concern doubts while advancing its life-support technologies.

Summary

• Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company focused on life-support technologies for acute respiratory failure.
• Key products include the INSPIRA ART (Augmented Life-support Respiratory Technology), INSPIRA ART100 (cardiopulmonary bypass system), and HYLA Blood Sensor.
• The INSPIRA ART system is in development, aiming to oxygenate blood directly, allowing patients to remain awake and spontaneously breathe, potentially reducing the need for invasive mechanical ventilation. It has not been tested in humans.
• The INSPIRA ART100 system received FDA 510(k) class II regulatory clearance in May 2024 for cardiopulmonary bypass procedures lasting 6 hours or less. It also received Israeli AMAR approval in July 2024.
• The HYLA blood sensor is designed for real-time, continuous monitoring of key blood parameters without blood draws, with clinical study completion announced in November 2025, showing 95% to 99% accuracy.
• The VORTX Orbiting Blood Oxygenation Delivery System received its first U.S. patent approval and aims to oxygenate blood without fiber membranes, reducing blood cell damage. In-vivo testing achieved over 99% gas exchange target in April 2025.
• The company reported its first-ever revenue of $289,000 for the year ended December 31, 2025, primarily from sales of INSPIRA ART100 systems and carts.
• Operating loss for 2025 was $13.6 million, an increase from $11.3 million in 2024.
• Net loss for 2025 was $13.2 million, compared to $11.05 million in 2024.
• Accumulated losses as of December 31, 2025, reached approximately $80 million.
• Cash and cash equivalents as of December 31, 2025, were $3.1 million, expected to fund operations through Q1 2026.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and dependence on external funding.
• A proposed acquisition of a liquid biopsy diagnostics business and a concurrent $15 million equity investment were announced in January 2026 but subsequently terminated in March 2026.
• A new wholly-owned subsidiary was established in March 2026 to transfer existing medical business activities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the company achieved its first revenue and significant regulatory and clinical milestones for its ART100 system, the substantial and increasing net losses, significant accumulated deficit, and explicit 'going concern' warning indicate severe financial challenges and high operational risk. The termination of a proposed acquisition and the expiration of a debenture further highlight funding uncertainties.

Positives

• Achieved first-ever revenue of $289,000 in 2025, primarily from INSPIRA ART100 system sales.
• INSPIRA ART100 received FDA 510(k) class II regulatory clearance in May 2024 and Israeli AMAR approval in July 2024.
• Successful first human treatment using the ART100 system at Westchester Medical Center in April 2025.
• ART100 approved for clinical validation by Israel's largest healthcare provider for organ transplant procedures in May 2025.
• ART100 completed full clinical evaluation and transitioned to budgeted procurement at a leading U.S. academic medical center in January 2026, following successful treatment of approximately 30 patients.
• Secured official vendor approval from Clalit Health Services (world's second-largest HMO) for ART100 procurement and deployment in February 2026.
• HYLA blood sensor clinical study completed in November 2025, demonstrating 95% to 99% accuracy across measured parameters.
• VORTX Orbiting Blood Oxygenation Delivery System received its first U.S. patent approval (16 novel claims) and achieved over 99% gas exchange in in-vivo testing in April 2025.
• Dual Lumen Cannula received patents in the U.S. (U.S. 11,541,159) and Japan (JP 7777598), with an application allowed in Israel.
• Received ISO 13485:2016 Standard Certification in July 2023, a requirement for EU regulatory approval.
• Secured binding purchase orders for ART100 systems: $22.5 million from a privately held company outside the U.S. (July 2025) and $27 million from a national ministry of health in Africa (August 2025), with revenue recognition expected in 2026.
• Established strategic distribution agreements with Innovimed (Europe), WAAS Group (Spain/Portugal), Glo-Med (U.S. states, Gulf States), and CIO MED GROUP (Central America).
• Collaboration with Ennocure showed 75% reduction in bacterial growth within four hours and 100% reduction within 24 hours in in-vitro testing for preventing bloodstream infections.
• Secured approximately $4.7 million in gross proceeds from a registered direct offering in February 2026.

Negatives

• Incurred significant operating losses of $13.6 million in 2025 and $11.3 million in 2024.
• Reported a net loss of $13.2 million in 2025, an increase from $11.05 million in 2024.
• Accumulated deficit of approximately $80 million as of December 31, 2025.
• Audited financial statements for 2025 contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Existing cash and cash equivalents of $3.1 million as of December 31, 2025, are only sufficient to fund operations through Q1 2026.
• The INSPIRA ART system has not yet been tested in humans and is not FDA cleared or approved.
• Proposed acquisition of a liquid biopsy diagnostics business and a $15 million equity investment, announced in January 2026, was terminated in March 2026.
• Regulatory submission for ART100 system to the United Arab Emirates Ministry of Health and Prevention failed to be delivered as of March 25, 2026, requiring a new submission process.
• Dependence on external funding for future operations, with no assurance of availability on acceptable terms.
• Significant increase in research and development expenses (18.6% increase to $7.5 million in 2025) and general and administrative expenses (32% increase to $5.5 million in 2025).
• Sales and marketing expenses decreased by 22% in 2025, potentially indicating reduced commercialization efforts or efficiency.
• The senior convertible debenture with the Target (Bio-View Ltd.) expired as of March 25, 2026, due to non-receipt of $5 million proceeds under the SEPA.

Risks

• Substantial doubt about the ability to continue as a going concern, which may prevent obtaining new financing.
• Limited operating history and significant operating losses since inception, with anticipated continued losses.
• Dependence on successful development, marketing, and sale of products, and obtaining required regulatory approvals.
• Potential failure to maintain Nasdaq listing due to minimum bid price requirement (received notice in February 2026, compliance required by August 10, 2026).
• Inability to generate significant revenue from product sales and potential unprofitability.
• Need to raise substantial additional funding, which may not be available on acceptable terms, leading to curtailment or discontinuation of product development.
• Medical device development is costly and involves continual technological change, potentially rendering products obsolete.
• Customer acquisition strategy may not succeed, and existing non-binding distribution agreements may not result in sales if products do not receive FDA clearance.
• Dependence on third-party service providers for manufacturing and supply, vulnerable to shortages, increased costs, and quality issues.
• Exposure to foreign currency exchange rate fluctuations.
• Reliance on a small number of employees and key consultants; difficulties in recruiting additional personnel could disrupt operations.
• International expansion exposes the business to regulatory, political, operational, financial, and economic risks.
• Inadequate coverage and reimbursement from third-party payors for products could negatively impact revenue.
• Extensive government regulation and oversight in the U.S. and abroad; failure to comply could harm the business.
• Delays or failure in receiving necessary regulatory clearances or approvals for products.
• Failure to comply with post-marketing regulatory requirements could lead to enforcement actions, penalties, or product recalls.
• Products may cause or contribute to adverse medical events, leading to product liability suits or regulatory sanctions.
• Healthcare legislative and regulatory reform measures may adversely affect the business.
• Inability to obtain and maintain effective patent rights or protect trade secrets could impair competitive position.
• Potential exposure to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws.
• Adverse effects from security breaches, including cybersecurity incidents.
• Political, economic, and military instability in Israel, where headquarters and R&D facilities are located, may adversely affect operations.
• Officers and directors beneficially own approximately 9.2% of ordinary shares, potentially exerting control over shareholder matters.
• Market price of securities is likely to be highly volatile.
• Future sales of ordinary shares could reduce market price and cause dilution.
• Never paid cash dividends and do not anticipate paying any in the foreseeable future.
• As an emerging growth company and foreign private issuer, the company may postpone compliance with some laws and reduce information provided, potentially undermining investor confidence.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to negative tax consequences for U.S. holders.
• Subject to securities litigation, which is expensive and could divert management attention.
• Inability to enforce covenants not-to-compete under Israeli law.
• Provisions of Israeli law and articles of association may delay or prevent mergers or acquisitions.
• Difficulty enforcing U.S. court judgments against the company and its officers/directors in Israel.
• Shareholder rights and responsibilities governed by Israeli laws, which differ from U.S. companies.
• Termination or reduction of tax and other incentives from the Israeli government could increase costs.
• May be required to pay monetary remuneration to Israeli employees for inventions.
• Restrictions on transfer of know-how and manufacturing outside of Israel due to government grants.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future, with expenses increasing due to ongoing clinical development, new regulatory applications, preclinical R&D, establishment of commercial infrastructure, hiring additional personnel, and intellectual property protection. It anticipates requiring substantial additional capital to fund operations for the next twelve months. The strategic goal is for the INSPIRA ART system to replace mechanical ventilators, with plans to pursue global regulatory approvals and strategic collaborations. The HYLA standalone device and INSPIRA ART disposables are targeted for FDA submission in 2026 and 2027, respectively. The company also plans a human observational study for the INSPIRA ART system. Revenue recognition from significant purchase orders is expected in the 2026 fiscal cycle.

Management Comments

• Our objective is to support patient treatment without the need for invasive mechanical ventilation and potentially reduce certain risks, complications, and costs associated with such interventions.
• We believe that the delivery of the INSPIRA ART100 in the U.S. market serves our goal is to introduce physicians and perfusionists to our technology and brand via initial deployments at leading hospitals.
• Our goal is to support healthcare systems by providing a practical and portable solution facilitating the treatment of respiratory failure, without the need for mechanical ventilation, and with the ability to deploy INSPIRA ART systems in and outside of ICUs to an ambulatory treatment that can be administered in all hospital wards as well as in ambulances.
• We believe that Saudi Arabia's dual strategy to invest $65 billion and further privatize its healthcare sector, or Vision 2030, signals that the Territory is a burgeoning market for medical innovation.
• We believe that it is not probable that a payment will be required to settle this matter [Nussinovitch lawsuit].

Industry Context

StockSavvy.ai notes that Inspira Technologies operates in the highly competitive and rapidly evolving medical device industry, specifically targeting the acute respiratory care market, which is projected to reach $16.09 billion by 2029. The company faces established competitors such as Boston Scientific, ResMed, Medtronic, and Johnson & Johnson, which possess significantly greater brand recognition, R&D, regulatory capabilities, and financial resources. Inspira's strategy to develop alternatives to traditional mechanical ventilation addresses a critical need, given the high mortality rates (exceeding 50% in some cases) and complications associated with prolonged ventilation. The focus on non-invasive, awake patient treatment with real-time monitoring (INSPIRA ART, HYLA) aligns with broader industry trends towards less invasive procedures and improved patient outcomes. However, the market's lack of innovation in the perfusionist sector, as highlighted by Inspira, presents an opportunity for the company's INSPIRA ART100 system.

Comparison to Industry Standards

• INSPIRA ART system is being developed as a potential alternative or complementary approach for patients with acute respiratory failure who currently require mechanical ventilation in ICUs, where mortality rates may exceed 50%.
• The HYLA blood sensor demonstrated 94.2% accuracy for continuous optical measurement of Partial Pressure of Carbon Dioxide (pCO) in advanced bench testing, aligning with clinical needs. Clinical study results showed 95% to 99% accuracy across measured parameters, which is a significant advancement from initial data.
• The VORTX technology aims to oxygenate blood without fiber membranes, which are known in current blood oxygenators to cause harmful turbulence, friction, and shear forces, leading to significant damage to blood components and cells (hemolysis, white blood cell damage, inflammatory/immune system activation, blood clotting). This suggests a potential improvement over existing fiber oxygenator designs.
• The proprietary dual lumen cannula design offers a novel approach to intravascular access by converting from single-lumen to dual-lumen through the same incision, potentially reducing patient risk, complications, and infection points compared to traditional methods requiring multiple incisions.
• Collaboration with Ennocure showed a 75% reduction in bacterial growth within four hours and a 100% reduction within 24 hours in in-vitro testing for preventing bloodstream infections, addressing an estimated 250,000 bloodstream infections related to intravenous lines worldwide each year.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit filed by Exchange against the company and former CFO Joe Hayon (March 4, 2022) for consultancy services related to IPO. Claims against Joe Hayon dismissed, breach of contract claims partially dismissed. Confidential settlement reached in July 2023, matter voluntarily dismissed.
• Lawsuit by the company against Dr. Udi Nussinovitch (February 24, 2022) for breach of good faith and fiduciary duties, and a counter-claim by Dr. Udi Nussinovitch against the company (November 9, 2022) alleging deficiencies in a 2021 shareholder meeting and seeking remuneration/issuance of Ordinary Shares. Mr. Nussinovitch's motion to amend his claim (January 7, 2025) to request purchase of his rights/shares was denied. Court partially granted motion to dismiss (May 7, 2025), dismissing claims deemed no longer relevant. Remaining declaratory claims and operative claim (entitlement to benefits granted to controlling shareholders) proceed, subject to court fees. Mr. Nussinovitch agreed to dismiss claims against directors on September 18, 2025. The company believes it is not probable that a payment will be required to settle this matter.

Related Party Transactions

• Employment agreements with executive officers contain customary provisions regarding noncompetition, confidentiality of information, and assignment of inventions.
• Indemnification agreements with executive officers and directors provide indemnification up to a certain amount and to the extent not covered by D&O insurance.
• Compensation paid to officers and directors in 2025: Dagi Ben-Noon ($335,262 salary, $23,775 pension, $666,059 share-based); Joe Hayon ($445,144 salary, $21,652 pension, $1,012,067 share-based); Yafit Tehila ($223,086 salary, $46,607 pension, $421,378 share-based); Avi Shabtai ($280,492 salary, $63,810 pension, $498,767 share-based); Daniella Yeheskely-Hayon ($215,958 salary, $45,666 pension, $408,146 share-based).
• Director fees for Tal Parnes (Chairman) increased to $80,000 annually, and for Lior Amit and Sivan Matza (non-executive directors) increased to $46,000 annually, approved in February and May 2025.
• Granted options and Restricted Share Units (RSUs) to officers and directors under the 2019 Equity Incentive Plan.
• Previous convertible loan agreement with IML, Founders, and Newburyport terminated in November 2020, with loan amounts converted into 676,061 Ordinary Shares and issuance of 80,273 promoter shares and options to Daniel Goldstein.
• Paid Newburyport and Peter Marks AUD 403,000 (approximately $321,000) each as cash commission for investor introductions as of November 28, 2021.
• Balances with related parties as of December 31, 2025, include $343,000 for officers' salaries and related liabilities and $41,000 for directors' compensation.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity offerings and warrant exercises, and the volatile share price. The 'going concern' warning raises concerns about investment recovery, though successful commercialization could yield long-term value.
• Employees may experience operational disruptions due to military reserve duty call-ups in Israel. The company's share-based compensation plans provide incentives, and there is potential for increased compensation due to intense competition for qualified personnel.
• Customers (hospitals/healthcare providers) could benefit from innovative life-support technologies (ART, HYLA, VORTX) that aim to improve patient care and reduce costs associated with traditional mechanical ventilation. However, they face risks related to potential product recalls or safety issues and dependence on third-party payor reimbursement.
• Suppliers and manufacturers face supply chain risks due to the company's dependence on third-party providers for components and assembly.
• Creditors face increased risk due to the company's recurring losses and the 'going concern' explanatory paragraph in its financial statements, indicating potential challenges in meeting future obligations.

Next Steps

• Submit HYLA standalone device for FDA regulatory clearance (second half of 2026).
• Additional U.S. hospital deployments for INSPIRA ART100 (first half of 2026).
• Submit INSPIRA ART blood flow disposable for FDA clearance (second half of 2026).
• Submit INSPIRA ART blood oxygenation disposable for FDA clearance (2027).
• Collaborate with top-ranking hospitals to perform a human observational study for INSPIRA ART system (pending approvals) to prevent patient deterioration and assist in weaning patients off mechanical ventilation.
• New regulatory submission process for ART100 system to the United Arab Emirates Ministry of Health and Prevention in the upcoming weeks.
• Expect payment and revenue recognition relating to the $22.5 million and $27 million purchase orders during the 2026 fiscal cycle.
• Transfer existing medical business activities into a newly formed wholly-owned subsidiary.

Key Dates

Recommendation

Inspira Technologies presents a high-risk, high-reward profile. While the company has achieved critical regulatory clearances for ART100 and demonstrated promising clinical and technical progress with its other innovative products (HYLA, VORTX), the substantial and increasing net losses, significant accumulated deficit, and explicit 'going concern' warning are major red flags. The company's ability to secure future funding on favorable terms is paramount. The large purchase orders are positive, but revenue recognition is deferred to 2026, and the termination of the liquid biopsy acquisition adds uncertainty. A 'Hold' recommendation is appropriate for seasoned investors who can tolerate high risk and are willing to monitor the company's progress in securing financing, achieving commercialization, and resolving its going concern issues. The long-term potential is significant if the company can overcome its financial hurdles and successfully bring its innovative products to market.

Keywords

Medical devices, Life support technology, Respiratory failure, Extracorporeal oxygenation, Cardiopulmonary bypass, Blood oxygenation, Blood sensor, FDA clearance, Regulatory approval, Acute respiratory care, Intensive care units (ICU), Ventilators, HYLA, INSPIRA ART, INSPIRA ART100, VORTX, Israel Innovation Authority (IIA), Nasdaq Capital Market, Going concern, Biomedical engineering, Healthcare technology